ATOS:US
$0.878
-0.847%
Atossa Therapeutics Inc.News & Events
Last updated: Jun 11, 2025, 11:44 PM ET
Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference
PR Newswire JUN 2, 2025 8:45 AM EDTAtossa Therapeutics to Present at the Jefferies Global Healthcare Conference PR Newswir...READ ARTICLEJoin Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22
ACCESS Newswire MAY 20, 2025 9:00 AM EDTSEATTLE, WASHINGTON / ACCESS Newswire / May 20, 2025 / Atossa Therapeutics, Inc. (Nasdaq:ATOS)...READ ARTICLEAtossa Therapeutics Announces Full Results from I?SPY?2 Endocrine?Optimization Sub?Study Evaluating Low?Dose (Z)?Endoxifen
PR Newswire MAY 14, 2025 8:15 AM EDTAtossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimizati...READ ARTICLEAtossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update
PR Newswire MAY 13, 2025 8:00 AM EDTAtossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Updat...READ ARTICLEAtossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio
GlobeNewswire APR 30, 2025 8:45 AM EDTSEATTLE, April 30, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Ato...READ ARTICLEAtossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025
GlobeNewswire APR 29, 2025 8:45 AM EDTSEATTLE, April 29, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Ato...READ ARTICLEAtossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio
GlobeNewswire APR 22, 2025 8:45 AM EDTSEATTLE, April 22, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Ato...READ ARTICLENona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer
PR Newswire APR 10, 2025 8:00 AM EDTNona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies f...READ ARTICLEAtossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update
GlobeNewswire MAR 25, 2025 8:00 AM EDTEnded 2024 with $71.1 million of cash and cash equivalents and no debt Conference Call an...READ ARTICLEAtossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire MAR 20, 2025 9:13 AM EDTSEATTLE, March 20, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Ato...READ ARTICLE